Weight Loss with Primary Hyperoxaluria Type 1 in South Africa
Primary Hyperoxaluria Type 1 (PH1) is a rare inherited liver disorder caused by mutations in the AGXT gene. Without the enzyme alanine:glyoxylate aminotransferase (AGT), the body overproduces oxalate — a waste product that cannot be broken down and must be excreted by the kidneys. The relentless oxalate load leads to calcium oxalate kidney stones, nephrocalcinosis (calcium deposits in kidney tissue), and without early treatment, progressive kidney failure. If you have PH1 and want to lose weight, this guide explains why your kidneys must be protected above all else, how diet and hydration interact with caloric restriction, and what practical steps are safe in the South African context.
What Is Primary Hyperoxaluria Type 1?
Oxalate is an end-product of metabolism that the human body cannot further break down. It is filtered by the kidneys and excreted in urine. When urinary oxalate is too high — either because of dietary overload or (in Primary Hyperoxaluria) endogenous overproduction — oxalate combines with calcium to form calcium oxalate crystals. These crystals deposit in the kidneys and urinary tract, causing:
- Recurrent kidney stones (nephrolithiasis) — often beginning in childhood
- Nephrocalcinosis — diffuse calcium oxalate deposits throughout kidney tissue, which progressively destroy nephrons
- Progressive chronic kidney disease leading to end-stage renal failure if untreated
- Systemic oxalosis — when kidney function declines severely, oxalate accumulates throughout the body, depositing in bones, joints, the heart, blood vessels, and skin
The root cause in PH1 is a deficiency of the liver enzyme alanine:glyoxylate aminotransferase (AGT), encoded by the AGXT gene on chromosome 2q37.3. AGT is located inside liver peroxisomes, where it converts glyoxylate (an intermediate in amino acid and lipid metabolism) into glycine. Without functional AGT, glyoxylate is not safely converted to glycine. Instead, it is oxidised to oxalate — and the liver becomes a factory for oxalate overproduction.
Urinary oxalate in PH1 is typically more than 0.5 mmol/1.73m²/day (the upper limit of normal is approximately 0.5 mmol/1.73m²/day). In severe cases, urinary oxalate exceeds 1–2 mmol/1.73m²/day. This is primarily endogenous overproduction — not dietary oxalate intake — which is why PH1 cannot be managed by diet alone, and why high-dose dietary oxalate restriction has a limited impact compared with secondary hyperoxaluria (where dietary absorption is the main issue).
PH1 vs Secondary Hyperoxaluria: A Critical Distinction
Not all high urinary oxalate is Primary Hyperoxaluria. Secondary hyperoxaluria is far more common and results from excessive dietary oxalate intake, fat malabsorption (in inflammatory bowel disease, short bowel syndrome, or bariatric surgery — where unabsorbed fat in the colon binds calcium, leaving oxalate free to be absorbed), or vitamin C mega-dosing (ascorbate is metabolised to oxalate).
In secondary hyperoxaluria, aggressive dietary oxalate restriction is highly effective. In PH1, the liver is generating oxalate from glyoxylate regardless of dietary intake. Dietary oxalate restriction in PH1 is still recommended (to reduce the dietary contribution), but the primary treatment strategies are:
- Pyridoxine (vitamin B6) therapy: In approximately 10–30% of PH1 patients, high-dose pyridoxine (typically 5–20 mg/kg/day, up to 400 mg/day) significantly reduces urinary oxalate. This is because an alternative enzyme (alanine:glyoxylate aminotransferase-2) that can compensate partially is pyridoxal-phosphate (active vitamin B6) dependent. Pyridoxine-responsive patients are typically those with certain AGXT missense mutations (particularly p.Gly170Arg). A trial of high-dose pyridoxine for 3 months with urinary oxalate monitoring is standard practice to identify responders.
- Lumasiran (Oxlumo): An RNA interference (RNAi) therapy approved in 2020–2021. Lumasiran targets hepatic glycolate oxidase (HAO1), reducing glyoxylate production. By reducing the substrate, it dramatically lowers urinary oxalate production regardless of whether a patient is pyridoxine-responsive. Lumasiran has been a landmark treatment advance, though it is expensive and availability in South Africa is limited.
- High fluid intake: A cornerstone of management to maintain dilute urine and prevent crystal formation. Targets are typically urine output of at least 3 litres per day in adults (adjusted for body size in children). This is essential year-round, and especially in South Africa's hot climate.
- Kidney-liver transplantation: For patients who progress to end-stage renal failure, combined liver-kidney transplantation corrects the enzymatic defect in the liver (eliminating the source of oxalate overproduction) while replacing the kidneys. Kidney transplantation alone is insufficient because the transplanted kidney is then exposed to the same oxalate overproduction.
How Weight and Kidney Function Interact in PH1
The kidneys are the critical organ in PH1. Protecting kidney function is the overriding priority in all management decisions, including weight management. Obesity in PH1 creates compounding risks:
- Increased metabolic oxalate production: Larger body mass means more glyoxylate flux through liver peroxisomes, which can increase endogenous oxalate production.
- Reduced glomerular filtration efficiency per nephron: Obesity is independently associated with hyperfiltration injury to the kidneys, which accelerates the nephron loss already occurring from oxalate deposition.
- Dehydration risk: Obesity is associated with reduced voluntary fluid intake relative to requirements. In PH1, dehydration is dangerous — concentrated urine dramatically increases calcium oxalate supersaturation and crystal formation risk.
Conversely, weight loss in PH1 can reduce metabolic oxalate production, improve kidney filtration efficiency, and reduce the risk of stone events. The key is that caloric restriction must be carefully managed to avoid dehydration and avoid dietary patterns that increase oxalate intake.
Dietary Management for Weight Loss in PH1
Work with your nephrologist and dietitian to establish an appropriate caloric deficit — typically 300–500 kcal/day — alongside your existing PH1 management plan. Key dietary principles:
Maintain Very High Fluid Intake — Non-Negotiable
Caloric restriction must never compromise fluid intake. In South Africa's warm climate, even minor fluid restriction can cause significant urinary concentration. Targets:
- Minimum 3 litres of fluid per day (adults); more in summer, after exercise, or in high-temperature environments
- Urine should remain pale yellow at all times — dark urine indicates inadequate hydration in PH1 and requires immediate fluid intake
- Spread fluid intake evenly through the day and night (some patients set an alarm to drink during the night to maintain urine dilution overnight)
- Water is ideal; rooibos tea is an excellent caffeine-free, low-oxalate South African option; avoid black tea (very high oxalate), spinach smoothies (extremely high oxalate), and high-dose vitamin C supplements (converted to oxalate)
Low-Oxalate Eating Pattern
While dietary oxalate contributes a minority of urinary oxalate in PH1, reducing high-oxalate foods provides incremental benefit:
- Eliminate very high oxalate foods: Spinach, Swiss chard, beetroot (a staple South African vegetable — unfortunately very high in oxalate), rhubarb, peanuts, nuts (particularly almonds, cashews, and peanuts), wheat bran, and dark chocolate/cocoa.
- Moderate oxalate foods (limit portions): Sweet potato, whole wheat bread, legumes, soya products, strawberries, and citrus peel.
- Low-oxalate foods to build meals around: Eggs, white rice, most meats and fish, most dairy products, cauliflower, cabbage, mushrooms, peas, broccoli, onions, and maize/mealie meal (white, not bran-enriched). These are all compatible with weight loss eating patterns.
Adequate Calcium Intake
A common error in oxalate management is reducing dietary calcium, in the mistaken belief that less dietary calcium means less calcium oxalate stone formation. In reality, dietary calcium taken with meals binds dietary oxalate in the gut, preventing oxalate absorption. Low-calcium diets actually increase urinary oxalate by reducing this gut-binding effect. Maintain normal dietary calcium intake (2–3 servings of dairy or calcium-fortified foods per day) with meals. Dairy products are also excellent, low-oxalate protein sources compatible with a weight-loss diet — full-cream yoghurt swapped for plain low-fat yoghurt, milk in rooibos rather than full-cream, etc.
Avoid Vitamin C Supplements
Ascorbic acid (vitamin C) is metabolised to oxalate. In PH1, even modest supplemental vitamin C can meaningfully increase urinary oxalate. Avoid vitamin C supplements entirely. Eat whole fruit and vegetables for dietary vitamin C instead.
Exercise in PH1
Physical activity is beneficial for weight management and does not directly trigger metabolic crises in PH1 (unlike fatty acid oxidation disorders). However, exercise increases fluid losses through sweating:
- Increase fluid intake by at least 500 mL for every 30 minutes of moderate exercise, or more in hot South African conditions.
- Drink during exercise, not only before and after.
- Monitor urine colour after exercise sessions — any darkening toward deep yellow or amber means you need more fluid before the next session.
- Activities that cause heavy sweating (outdoor running in summer, high-intensity interval training) carry higher dehydration risk than swimming or indoor gym sessions with climate control.
If your GFR (glomerular filtration rate) is significantly reduced, discuss exercise intensity limits with your nephrologist — severely impaired kidneys may require modified activity recommendations.
South African Context
South Africa's climate is a genuine PH1 risk factor. The Highveld (Gauteng, Mpumalanga) has hot, dry summers; the Northern Cape and Limpopo are hot year-round. Inadequate fluid intake in these conditions can rapidly concentrate urine to dangerous oxalate supersaturation levels. Make fluid intake a non-negotiable daily habit — set phone reminders, carry a measured water bottle, and increase intake immediately when the weather is hot or after outdoor activity.
PH1 should be managed at a specialist centre with metabolic and nephrology expertise. Wits Donald Gordon Medical Centre, Groote Schuur Hospital (UCT), and Steve Biko Academic Hospital (Pretoria) have nephrology units that handle rare kidney disorders. Ask for a referral to a metabolic dietitian experienced with hyperoxaluria.
Key Takeaways
- PH1 is caused by AGXT gene mutations — the liver overproduces oxalate because glyoxylate cannot be safely converted to glycine.
- The primary risk is progressive kidney damage from calcium oxalate crystal deposition.
- 10–30% of PH1 patients are pyridoxine-responsive — always check before diet alone is relied on.
- Fluid intake (minimum 3 L/day, more in South African heat) is the most critical daily management action.
- A low-oxalate diet helps at the margins; avoid very high oxalate foods (spinach, beetroot, nuts).
- Maintain adequate dietary calcium — it reduces gut oxalate absorption.
- Never reduce fluid intake to create a caloric deficit — only reduce calories from food.
- A 300–500 kcal/day deficit is appropriate for gradual weight loss while protecting kidney function.
- Consult your nephrologist and metabolic dietitian before making dietary changes.
This article is for educational purposes only and does not replace individualised advice from your nephrologist or metabolic dietitian. Dietary management of Primary Hyperoxaluria requires ongoing monitoring of urinary oxalate, kidney function, and calcium oxalate supersaturation.